BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8386239)

  • 1. Opioid receptor regulation in mice.
    Yoburn BC; Billings B; Duttaroy A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
    Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
    Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
    Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
    Duttaroy A; Yoburn BC
    Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.
    Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1992 Jul; 262(1):1-9. PubMed ID: 1625189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment.
    Tao PL; Law PY; Loh HH
    J Pharmacol Exp Ther; 1987 Mar; 240(3):809-16. PubMed ID: 3031275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased analgesic potency of mu agonists after continuous naloxone infusion in rats.
    Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1991 Nov; 259(2):582-9. PubMed ID: 1658305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
    Stafford K; Gomes AB; Shen J; Yoburn BC
    Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
    Zhang Q; Purohit V; Yoburn BC
    Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
    Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
    J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
    Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
    Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil.
    Freye E; Neruda B; Smith OW
    Arzneimittelforschung; 1997 Jan; 47(1):6-9. PubMed ID: 9037435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
    Chan KW; Duttory A; Yoburn BC
    Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal tolerance and unidirectional non-cross-tolerance in narcotic pellet-implanted mice.
    Lange DG; Roerig SC; Fujimoto JM; Busse LW
    J Pharmacol Exp Ther; 1983 Jan; 224(1):13-20. PubMed ID: 6681541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.
    Windh RT; Little PJ; Kuhn CM
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
    Barrett AC; Smith ES; Picker MJ
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of intrinsic efficacy on opioid tolerance.
    Duttaroy A; Yoburn BC
    Anesthesiology; 1995 May; 82(5):1226-36. PubMed ID: 7741298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of morphine but not fentanyl with cerebral alpha2-adrenoceptors in alpha2-adrenoceptor knockout mice.
    Höcker J; Böhm R; Meybohm P; Gruenewald M; Renner J; Ohnesorge H; Scholz J; Bein B
    J Pharm Pharmacol; 2009 Jul; 61(7):901-10. PubMed ID: 19589232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.